Rafferty Asset Management LLC Sells 28,806 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Rafferty Asset Management LLC lowered its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 20.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 109,236 shares of the biotechnology company's stock after selling 28,806 shares during the quarter. Rafferty Asset Management LLC owned 0.11% of Sarepta Therapeutics worth $13,282,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the business. Capital International Investors increased its position in Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after acquiring an additional 2,437,855 shares during the period. Norges Bank bought a new stake in shares of Sarepta Therapeutics in the fourth quarter worth $126,315,000. Farallon Capital Management LLC increased its holdings in Sarepta Therapeutics by 11.1% in the fourth quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company's stock valued at $348,368,000 after purchasing an additional 285,100 shares during the period. Alkeon Capital Management LLC increased its holdings in Sarepta Therapeutics by 34.7% in the fourth quarter. Alkeon Capital Management LLC now owns 853,845 shares of the biotechnology company's stock valued at $103,819,000 after purchasing an additional 220,000 shares during the period. Finally, Brandywine Global Investment Management LLC bought a new position in Sarepta Therapeutics during the 4th quarter worth $22,613,000. Institutional investors own 86.68% of the company's stock.

Insiders Place Their Bets

In other news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. This trade represents a 8.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 7.70% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on SRPT. Deutsche Bank Aktiengesellschaft decreased their price target on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research note on Wednesday, March 19th. JPMorgan Chase & Co. reduced their target price on Sarepta Therapeutics from $169.00 to $84.00 and set an "overweight" rating on the stock in a report on Tuesday. Morgan Stanley lowered their price target on shares of Sarepta Therapeutics from $182.00 to $113.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. UBS Group dropped their price target on shares of Sarepta Therapeutics from $188.00 to $85.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Finally, Guggenheim decreased their price objective on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Six equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $122.61.

Sarepta Therapeutics Stock Down 2.2%

NASDAQ:SRPT traded down $0.87 on Thursday, hitting $39.18. The stock had a trading volume of 1,504,733 shares, compared to its average volume of 1,766,642. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 52 week low of $34.10 and a 52 week high of $173.25. The business's fifty day moving average is $56.56 and its 200 day moving average is $95.81. The company has a market cap of $3.85 billion, a PE ratio of 31.42 and a beta of 0.85.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The firm had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. During the same quarter in the prior year, the business earned $0.73 earnings per share. Sarepta Therapeutics's revenue for the quarter was up 80.2% on a year-over-year basis. On average, equities research analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.